PMGC Holdings Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/28/2026 16:00

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization3.66 mln

Float0.81 mln

Earnings Date11/13/2026

Piotroski F-Score

3 / 9

Below average

Relative Strength

83 / 100

Strongly outperforming

Debt / Equity

0.85

Moderate leverage

Pre-Tax Margin

-525%

Severely loss-making

ROE

-123

Deeply negative

Altman Z-Score

-1.83

Deeply distressed

Business Description

PMGC Holdings Inc., formerly Elevai Labs Inc., is a Newport Beach-based biopharmaceutical company founded in 2020 that develops and acquires innovative treatments in aesthetics and medicine. Its lead candidate, EL-22, is a first-of-its-kind engineered probiotic designed to help patients on weight loss drugs, such as GLP-1 receptor agonists, retain muscle mass during treatment. The company also conducts medical research and runs investment operations.

Key Fundamentals

EPS-1,827

ROE-123

RPS19.08

ROIC-91.36

ROA-67.58

Interest Cover-5.56

EBITDA, mln-11.66

EV / EBITDA0.02

EV / EBIT0.02

Revenue, mln2.58

Quote Details

Last 4.78

Change 0.21 (4.6%)

Open 4.54

Volume 248,275

Turnover 1,186,754

Average Volume 43,516

Financial Ratios

Pre-Tax Profit Margin-525

Leverage Ratio2.18

Current Ratio1.36

Price / Book0.20

Price / Tangible Book0.43

Debt / Equity0.85

Price / Sales0.03

Financial Strength

Altman Z-Score-1.83

Piotroski F-Score 3 / 9

Short Ratio0.56

Short % of Float4.25

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	8.14%	95 / 100
1 Month	-18.01%	13 / 100
2 Months	-64.59%	4 / 100
6 Months	-71.38%	4 / 100
1 Year	-99.6%	1 / 100